339 related articles for article (PubMed ID: 37863379)
1. Evaluation of immune response to SARS-CoV-2 Omicron sublineages six months after different vaccination regimens in Italy.
Trombetta CM; Marchi S; Leonardi M; Coppola C; Benincasa L; Marotta MG; Buonvino N; Maes P; Stufano A; Pontrelli D; Vasinioti VI; Manenti A; Camero M; Montomoli E; Decaro N; Lovreglio P
Acta Trop; 2023 Dec; 248():107042. PubMed ID: 37863379
[TBL] [Abstract][Full Text] [Related]
2. Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1.
Hu Y; Zou J; Kurhade C; Deng X; Chang HC; Kim DK; Shi PY; Ren P; Xie X
Emerg Microbes Infect; 2023 Dec; 12(2):2271089. PubMed ID: 37824708
[TBL] [Abstract][Full Text] [Related]
3. Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.
Bellusci L; Grubbs G; Sait S; Yonker LM; Randolph AG; Novak T; Kobayashi T; ; Khurana S
Nat Commun; 2023 Dec; 14(1):7952. PubMed ID: 38040697
[TBL] [Abstract][Full Text] [Related]
4. Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity.
Muik A; Lui BG; Quandt J; Diao H; Fu Y; Bacher M; Gordon J; Toker A; Grosser J; Ozhelvaci O; Grikscheit K; Hoehl S; Kohmer N; Lustig Y; Regev-Yochay G; Ciesek S; Beguir K; Poran A; Vogler I; Türeci Ö; Sahin U
Cell Rep; 2023 Aug; 42(8):112888. PubMed ID: 37527039
[TBL] [Abstract][Full Text] [Related]
5. Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023.
Fabiani M; Mateo-Urdiales A; Sacco C; Rota MC; Fotakis EA; Petrone D; Del Manso M; Siddu A; Stefanelli P; Bella A; Riccardo F; Rezza G; Palamara AT; Brusaferro S; Pezzotti P;
Euro Surveill; 2023 Aug; 28(32):. PubMed ID: 37561053
[TBL] [Abstract][Full Text] [Related]
6. Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.
Cheng SMS; Mok CKP; Li JKC; Chan KKP; Luk KS; Lee BHW; Gu H; Chan KCK; Tsang LCH; Yiu KYS; Ling KKC; Tang YS; Luk LLH; Yu JKM; Pekosz A; Webby RJ; Cowling BJ; Hui DSC; Peiris M
Virol J; 2024 Mar; 21(1):70. PubMed ID: 38515117
[TBL] [Abstract][Full Text] [Related]
7. Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1.
Sullivan DJ; Franchini M; Senefeld JW; Joyner MJ; Casadevall A; Focosi D
J Gen Virol; 2023 May; 104(5):. PubMed ID: 37167085
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
[TBL] [Abstract][Full Text] [Related]
9. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
[TBL] [Abstract][Full Text] [Related]
10. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
11. Boosting with variant-matched adenovirus-based vaccines promotes neutralizing antibody responses against SARS-CoV-2 Omicron sublineages in mice.
Shin KS; Kim BS; Chang S; Jung IK; Park H; Park S; Shin J; Kim JH; Han SJ; Park B; Kim JO; Lee JA; Lee TY; Kang CY
Int J Antimicrob Agents; 2024 Mar; 63(3):107082. PubMed ID: 38163552
[TBL] [Abstract][Full Text] [Related]
12. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
Lancet Infect Dis; 2023 Jul; 23(7):799-805. PubMed ID: 36924786
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Neutralization Capacity in Hemodialysis Patients with and without a Fifth Vaccination with the Updated Comirnaty Original/Omicron BA.4-5 Vaccine.
Liao BH; Platen L; Grommes M; Cheng CC; Holzmann-Littig C; Christa C; Haller B; Kappler V; Bester R; Werz ML; Platen E; Eggerer P; Tréguer L; Küchle C; Schmaderer C; Heemann U; Renders L; Protzer U; Braunisch MC
Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543942
[TBL] [Abstract][Full Text] [Related]
14. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
[TBL] [Abstract][Full Text] [Related]
15. Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4/5 Bivalent Booster.
Machado RRG; Candido ÉD; Aguiar AS; Chalup VN; Sanches PR; Dorlass EG; Amgarten DE; Pinho JRR; Durigon EL; Oliveira DBL
Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400128
[TBL] [Abstract][Full Text] [Related]
16. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB
Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540
[TBL] [Abstract][Full Text] [Related]
17. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
[TBL] [Abstract][Full Text] [Related]
18. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.
Kurhade C; Zou J; Xia H; Liu M; Chang HC; Ren P; Xie X; Shi PY
Nat Med; 2023 Feb; 29(2):344-347. PubMed ID: 36473500
[TBL] [Abstract][Full Text] [Related]
19. Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages.
Guo L; Zhang Q; Zhong J; Chen L; Jiang W; Huang T; Li Y; Zhang Y; Xu L; Wang X; Xiao Y; Wang Y; Dong X; Dong T; Peng Y; Zhang B; Xie Y; Gao H; Shen Z; Ren L; Cheng T; Wang J
Emerg Microbes Infect; 2023 Dec; 12(1):2202263. PubMed ID: 37037791
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 Variants Omicron BA.4/5 and XBB.1.5 Significantly Escape T Cell Recognition in Solid-organ Transplant Recipients Vaccinated Against the Ancestral Strain.
Halvorson T; Ivison S; Huang Q; Ladua G; Yotis DM; Mannar D; Subramaniam S; Ferreira VH; Kumar D; Belga S; Levings MK;
Transplantation; 2024 Apr; 108(4):e49-e62. PubMed ID: 38012843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
